- Home
- AIIA vs MGNX Comparison
AIIA vs MGNX Comparison
Compare AIIA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIIA | MGNX |
|---|---|---|
| Founded | 2025 | 2000 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.9M | 220.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | AIIA | MGNX |
|---|---|---|
| Price | $10.17 | $3.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 29.6K | ★ 915.6K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $1.19 |
| 52 Week High | $10.24 | $4.64 |
Technical Indicators
Market Signals| Indicator | AIIA | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 52.36 |
| Support Level | $10.06 | $1.49 |
| Resistance Level | $10.20 | $4.55 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 78.57 | 21.21 |
Price Performance
Historical ComparisonAbout AIIA AI Infrastructure Acquisition Corp. Class A Ordinary Shares
AI Infrastructure Acquisition Corp is a blank check company.
About MGNX MacroGenics Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.